



Thursday, November 3, 2005

9:30 – 11:00 **Case Studies in Onychomycosis**
Salle de Bal Centre & Est

Session Objectives:

Review & discuss treatment options from case presentations.

Treatments for standard as well as more complex cases will be discussed including:

- Relapse & recurrence
- Onychomycosis in children
- Hyperkeratotic & onycholytic nails
- Dermatophytoma with Lunular Involvement
- The diabetic patient

Audience treatment opinions will be presented through touch pad response.

Faculty:

Dr. Kirk Barber – chair

Dr. Aditya Gupta – speaker

Dr. Ron Vender – speaker

Agenda:

9:30	Introduction	Dr. Kirk Barber
9:35	Case presentations with Q&A after each case	Dr. Ron Vender
10:15	Case presentations with Q&A after each case	Dr. Aditya Gupta
10:55	Summary	Dr. Kirk Barber



Thursday, November 3, 2005

2:00 – 3:30 **Shaping the Management of Psoriasis – Achieving Long-Term Control with Efalizumab**
Salle de Bal Centre & Est

Meeting Objectives:

After participating in this workshop, participants should better understand:

- The mechanism of action of efalizumab.
- The benefit/risk of efalizumab based on the safety and efficacy clinical data.
- The strategies for optimizing patient treatment with efalizumab.
- Patient/Treatment selection considerations based on the differences among biologicals, with regards to safety, efficacy and convenience.

Faculty:

Yves Poulin, MD, FRCPC; Wayne Gulliver, MD, FRCPC; Kim Papp, MD, PhD, FRCPC; Neil Shear, MD, FRCPC

Program:

- 2:00 pm Chair Welcome and Introduction: Long-term Control – An Unmet Need in Psoriasis
Yves Poulin, MD, FRCPC
- 2:10 pm A Favourable Benefit/Risk Ratio with Efalizumab – A Targeted T-cell Agent
Wayne Gulliver, MD, FRCPC
- 2:30 pm Strategies for Optimizing Treatment of Efalizumab
Kim Papp, MD, PhD, FRCPC
- 2:50 pm Not All Biologics Are the Same – Patient/Treatment Selection Considerations
Neil Shear, MD, FRCPC
- 3:10 pm Question and Answer
- 3:25 pm Closing Comments
Yves Poulin, MD, FRCPC



Thursday, November 3, 2005

4:00 – 5:30 **Taking Control over Eczema: How to Meet Patients' Needs**
Salle de Bal Centre & Est

Meeting Objectives:

At the end of this session the participants will be able to:

- Review and discuss the gap existing in the current treatment of eczema and the patients' needs
- Evaluate the factors to consider in treating and managing the disease and how to provide patients with an approach to take control over their condition
- Review data from the continuous developments and ongoing studies in the treatment of eczema.

Faculty:

Dr. Neil Shear, MD, FRCPC, FACP

Helen and Paul Phelan Professor & Chief of Dermatology of Sunnybrook and Women's College Health Sciences Centre,
Professor of Medicine, Pharmacology, Pediatrics and Pharmacy
University of Toronto

Dr. Lawrence Eichenfield, MD

Professor of Pediatrics and Medicine (Dermatology)

Chief, Pediatric and Adolescent Dermatology

University of California, San Diego School of Medicine and
Children's Hospital, San Diego

Agenda:

4:00 pm to 4:15 pm	The Eczema Continuum	Dr. Neil Shear MD, FRCPC, FACP
4:15 pm to 4 :35 pm	Factors to consider when choosing a treatment	Dr. Lawrence F. Eichenfield, M.D.
4 :35 pm to 4:55 pm	Providing long-term control	Dr. Lawrence F. Eichenfield, M.D.
4 :55 pm to 5 :15 pm	The future in the treatment of eczema	Dr Neil Shear MD, FRCPC, FACP
5 :15 pm to 5 :30 pm	Q & A session	Dr. Lawrence F. Eichenfield, M.D. Dr. Neil Shear MD, FRCPC, FACP



Thursday, November 3, 2005 (continued...)

4:00 – 5:30 **Taking Control over Eczema: How to Meet Patients' Needs**
Salle de Bal Centre & Est

The Eczema Continuum: Dr. Neil Shear

Objectives :

At the end of this presentation the participants will be able to:

- Measure how the progression of the disease over a life-time, impacts the severity of its clinical manifestations.
- Describe the pathophysiological mechanisms involved in the pathogenesis of atopic eczema.

Factors to consider when choosing a treatment: Dr. Eichenfield

Objectives:

At the end of this presentation the participant will be able to:

- Discuss the impact of atopic eczema on patients quality of life and its effect on the healthcare system.
- Review available evidence of efficacy, safety and tolerability with current treatment in treating patient with atopic eczema.

Providing long-term control: Dr. Eichenfield

Objectives:

At the end of this presentation the participant will be able to:

- Assess the factors which influence the evaluation of disease severity.
- Discuss the rationale behind the early use management of pimecrolimus to take control of flare and reduce the use of topical corticosteroids.

The future in the treatment of eczema: Dr. Shear

Objectives:

At the end of this presentation the participant will be able to:

- Review current and future studies aiming at clarifying mechanism of atopic dermatitis and its treatment/management avenue.



Friday, November 4, 2005

9:30 – 11:00 **New Comparative Data in the Treatment of NMSC and Insights into the Future**
Salle de Bal Centre & Est

Meeting Objectives:

- Present advanced immunological update.
- Review progression of AK to SCC.
- Review new long-term data for imiquimod.
- Examine new data including an investigator initiated comparative study of topical treatments for actinic keratosis.

Faculty:

Dr. Jason Rivers, MD, FRCPC, Dr. Eggert Stockfleth, Dr. Mark Tomai

Agenda:

9:30	Welcome and Introduction	Dr. Jason Rivers
9:35 – 10:05	Tolls "R" Us	Dr. Mark Tomai
10:05 – 10:35	Clinical Advances in the Treatment of AK	Prof. Eggert Stockfleth
10:35 – 10:55	Questions and Discussion	
10:55	Closing Comments	Dr. Jason Rivers



Friday, November 4, 2005

11:30 – 1:30 **Psoriatic Arthritis and Psoriasis - A 2005 Clinical Management**
Salle de Bal Centre & Est

Learning Objectives:

By attending this symposium, participants will be able to:

- Interpret recent clinical trial data for anti-TNF agents used in the treatment of psoriatic arthritis and psoriasis
- Identify strategies for optimizing management of patients with psoriasis and/or psoriatic arthritis in clinical practice
- Discuss and share clinical experience with expert colleagues.

Faculty:

Dr. Ian Landells, MD, FRCPC
Clinical Assistant Professor
Faculty of Medicine, Memorial University
St. John's, Newfoundland

Dr. Philip J, Mease, MD
Chief of Rheumatology Clinical Research
Swedish Hospital Medical Center
Seattle, Washington

Dr. Alexa B Kimball, MD, MPH
Chair & Director, Clinical Unit for Research
Trials in Skin
Massachusetts General and Brigham &
Women's Hospitals
Harvard Medical School
Boston, Massachusetts

Friday, November 4, 2005 (continued...)

11:30 – 1:30 **Psoriatic Arthritis and Psoriasis - A 2005 Clinical Management**
Salle de Bal Centre & Est

Agenda:

11:30 Introduction, Learning Objectives
Chair: Dr. Ian Landells

11:35 Psoriatic Arthritis Clinical Update –
New Learnings from the Introduction of TNF Antagonists
Dr. Philip Mease

12:30 Psoriasis Clinical Update –
Interpreting the Latest Clinical Data
Dr. Alexa Kimball

13:10 Question and Answers

13:30 Adjourn

Friday, November 4, 2005

2:00 – 3:30 **AMEVIVE™: Redefining Efficacy in Psoriasis through Remission**
Salle de Bal Centre & Est

Psoriasis is a serious disease that has a severe impact on quality of life. Medications for psoriasis can be broken up into two groups: those that are remittive and those that are suppressive. Remittive therapies allow patients to have freedom from their disease for a period of time.

This session will explore AMEVIVE™, the only biologic currently approved by Health Canada for the treatment of chronic plaque psoriasis. AMEVIVE™ is a remittive therapy that can be self-administered by the patient and easily incorporated into the Dermatologist's daily practice.

Faculty:

Dr. Wayne Carey, Dr. Jennifer Cather, Dr. M. Khraishi, Dr. Charles Lynde

Agenda:

- 14:00 Opening
Dr. Wayne Carey
- 14:10 US experience with biologics
Dr. Jennifer Cather
- 14:40 New Data: Psoriatic Arthritis and Amevive
Dr. M. Khraishi
- 14:55 Amevive in Your Practice
Dr. Charles Lynde
- 15:10 Questions
- 15:25 Closing
- 15:30 Adjourn

Saturday, November 5, 2005

7:00 Breakfast (Salle de Bal Ouest)

SESSION 1

Chair: Dr. Chuck Lynde

- | | | |
|------|--|---------------------|
| 8:00 | Opening Remarks | |
| 8:05 | Review of Drugs for the Treatment of Skin Disease (2005) | Dr. Stuart Maddin |
| 8:25 | Intravenous Immunoglobulin Therapy: Past, Present and Future | Dr. Neil Shear |
| 8:45 | Latest Developments in Oral Antiviral Therapies | Dr. Charles Lynde |
| 9:05 | Herpes Zoster and Post Herpetic Neuralgia | Dr. Lyn Guenther |
| 9:25 | Alefacept: Redefining the Treatment of Psoriasis | Dr. Jennifer Cather |
| 9:45 | Panel and Questions | |

10:05 Coffee Break (Salle de Bal Foyer)

SESSION 2

Chair: Dr. Jan Dutz

- | | | |
|-------|--|-------------------|
| 10:25 | Psoriatic Arthritis Update | Dr. Phil Mease |
| 10:55 | Calcipotriol: Past, present and future | Dr. Karin Hamberg |
| 11:15 | What would be the #1 question you would ask Health Canada? | Dr. Norman Viner |
| 11:35 | Panel and Questions | |

12:00 RAPID FIRE LUNCH

SESSION 3

Chair: Dr. Wayne Carey

- | | | |
|------|---|------------------------|
| 2:00 | Efalizumab in the treatment of psoriatic disease: Clinical Update | Dr. Robert Bissonnette |
| 2:20 | Tacrolimus Ointment (Protopic®) in Atopic Dermatitis | Dr. Sakari Reitamo |
| 2:40 | Advocacy - What are the core issues? | Mr. Denis Morrice |
| 3:00 | Panel and Questions | |

3:15 Coffee Break (Salle de Bal Foyer)

SESSION 4

Chair: Dr. Jerry Tan

- | | | |
|------|--|--------------------|
| 3:35 | Hormonal effectiveness in treatment of acne | Dr. Jerry Tan |
| 3:55 | The Skin, A Target for Trace Elements – <i>Clinical Applications</i> | Dr. Brigitte Dreno |
| 4:15 | New Treatment Modalities for Non-Melanoma Skin Cancer | Dr. Jason Rivers |
| 4:35 | Panel and Questions | |
| 4:50 | Closing Comments | |

7:30 Gala Dinner (Salle de Bal Ouest, by pre-registration only)

Sunday, November 6, 2005

8:30 – 10:55 **The Changing Face of Dermatology Clinical Trials in Canada**
(pre-registration required, FEE: \$150+gst) – Salon 1, Level 2

This year we will focus on the conduct of specialty trials in the following areas: biologics, vaccines, and botulinum toxin trials. In addition we will look at the need for inter-rater reliability training in the conduct of acne and atopic dermatitis trials. Site selection is a critical element in ensuring a successful clinical trial program, and factors influencing selection of sites will be discussed from both investigator and industry perspectives.

We are privileged to have Dr. Norman Viner with us this year who will give a talk on the role of Health Canada in the conduct of clinical trials.

The Dermatology Update Clinical Trials Workshop is an interactive session. Participants are encouraged to ask questions and make comments. Workshop registration is open to both dermatologists and industry participants with an interest in clinical research.

Chairman: Lynne Bulger

Co chair: Dr. Paul Kidson

Agenda:

8:30	Welcome and introduction	Lynne Bulger
8:35	Challenges in the conduct of biologic trials.	Dr. Wayne Gulliver
8:55	Challenges in the conduct of vaccine trials.	Dr. Chuck Lynde
9:15	Challenges in the conduct of Botox trials.	Dr. Kevin Smith
9:35	<i>Break</i>	
9:45	Inter-rater reliability in acne and atopic dermatitis trials.	Lynne Bulger
10:10	Factors influencing site selection	Dr. Paul Kidson
10:35	The role of Health Canada in the conduct of clinical trials.	Dr. Norman Viner <i>Clinical Trial Division Chief HPFB, Health Canada</i>
10:55	Summary and close	Dr. Stuart Maddin